Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 314
- Registration Number
- NCT02526953
Bleb Function and Morphology With Intratendon Injection of MMC Compared With Standard Method
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 126
- Registration Number
- NCT02385370
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT02369458
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 118
- Registration Number
- NCT02369939
- Locations
- 🇩🇪
Universitaetsklinikum Erlangen, Strahlenklinik, Erlangen, Germany
CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)
- Conditions
- Interventions
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Viralytics
- Target Recruit Count
- 16
- Registration Number
- NCT02316171
- Locations
- 🇬🇧
University of Surrey, Guildford, United Kingdom
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2015-12-03
- Target Recruit Count
- 18
- Registration Number
- NCT02311101
- Locations
- 🇺🇸
The University of Texas Health Science Center, San Antonio, Texas, United States
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- Drug: AZD2014Drug: AnthracyclinesDrug: MEDI4736Drug: AZD4547Drug: TaxanesDrug: AZD5363Drug: cyclophosphamideDrug: DNA intercalatorsDrug: AZD8931Drug: SelumetinibDrug: MethotrexateDrug: vinca alkaloidsDrug: VandetanibDrug: Platinum based chemotherapiesDrug: BicalutamideDrug: OlaparibDrug: BevacizumabDrug: Mitomycin CDrug: Eribulin
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
Study of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT02287389
- Locations
- 🇨🇳
Tangdu Hospital, Xi'an, Shaanxi, China
Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 18
- Registration Number
- NCT02199327
- Locations
- 🇲🇽
IMSS Centro Médico de Occidente, Guadalajara, Jalisco, Mexico
Therapeutic Instillation of Mistletoe
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Abnoba Gmbh
- Target Recruit Count
- 548
- Registration Number
- NCT02106572
- Locations
- 🇩🇪
Urologische Praxis, Herzberg, Germany
🇪🇬Theodor Bilharz Research Institute, Giza, Egypt
🇩🇪Urologische Gemeinschaftspraxis, Heinsberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.